MYOV News and Press, Myovant Sciences Ltd. From 04/12/21

SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 years Contraceptive potential of relugolix combination tablet supported by prior Phase 1 study that...

Myovant Sciences (MYOV) appointed Lauren Merendino as Chief Commercial Officer, effective today; she has 20+ years of pharmaceutical and biotech leadership experience.Most recently, she served as VP, Neurological Rare Diseases at Genentech."The recent FDA approval in advanced p...

BASEL, Switzerland, April 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Lauren Merendino as Chief Commercial Officer of Myovant Sciences, Inc., effective April 5, 202...

A recent paper purports to show that academic research into factors is valid and that its results are replicable. I take a close look at the paper and read between the lines. I find that the authors' conclusions, while flawed, are valid and telling, and support the thesis that fac...

If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in Europe Relugolix is FDA-approved and currently available in the U.S. under the trade name ORGOVYX™ Pfizer has an exclusive option to commercializ...

Myovant Sciences (MYOV) and Pfizer (PFE) announce positive data from Phase 3 LIBERTY withdrawal study of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids. The LIBERTY randomized withdrawal study met its prima...

78.4% of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who discontinued treatment at Week 52 (p < 0.0001) 69.8% of women who continued relugolix combination therapy remai...

BASEL, Switzerland, March 23, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the four recipients of its Forward for Health Equity grants. The grant program provides funding to nonprofit heal...

Myovant Sciences (MYOV) and Pfizer (PFE) announces publication of Phase 3 LIBERTY 1 and LIBERTY 2 studies of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with uterine fibroids in the New England Journal of Medicine.LIBERTY 1 a...

LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline Achieved six of seven key secondary endpoints including reduction of pain Bone mineral density maintained at levels comparable to pla...